Atug Ozlen, Akin Hakan, Alahdab Yesim Ozen, Ceyhan Berrin, Tozun Nurdan, Ozdogan Osman
Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkey.
Cases J. 2009 Mar 10;2:6464. doi: 10.1186/1757-1626-0002-0000006464.
Interstitial pneumonitis is a rare but potentially fatal side effect occurring from 2 weeks to 16 weeks after the initiation of treatment with pegylated interferon alpha and ribavirin for chronic hepatitis C.Herein, we present a 68-year-old man with chronic hepatitis C virus infection who developed interstitial pneumonitis association with pegylated interferon after 36 weeks initiation of pegylated interferon-alpha and ribavirin therapy. He did not recover after discontinuation of pegylated interferon/ribavirin and improved by steroid therapy.
间质性肺炎是聚乙二醇化干扰素α和利巴韦林治疗慢性丙型肝炎开始后2周~16周出现的一种罕见但可能致命的副作用。在此,我们报告一名68岁慢性丙型肝炎病毒感染男性患者,在聚乙二醇化干扰素α和利巴韦林治疗开始36周后发生了与聚乙二醇化干扰素相关的间质性肺炎。停用聚乙二醇化干扰素/利巴韦林后他未恢复,经类固醇治疗后病情改善。